| Aaron Fry, DO | |
|
901 N Porter Ave, Norman, OK 73071-6404 | |
| (405) 307-1000 | |
| Not Available |
| Full Name | Aaron Fry |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 901 N Porter Ave, Norman, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225401292 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0071R (Oklahoma) | Primary |
| 207P00000X | Emergency Medicine | OP61498304 (Washington) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's Regional Medical Center | Enid, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospitalist Medicine Physicians Of Oklahoma Tcs Llc | 7315315454 | 13 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
| Entity Name | Emergency Staffing Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477590974 PECOS PAC ID: 9830001650 Enrollment ID: O20050207000313 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
| Entity Name | Emergency Services Of Oklahoma Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215249891 PECOS PAC ID: 8123209012 Enrollment ID: O20110225000085 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
| Entity Name | Mercy Hospital Logan County, Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306126818 PECOS PAC ID: 4587836200 Enrollment ID: O20111111000638 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
| Entity Name | Mercy Hospital Logan County, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306126818 PECOS PAC ID: 4587836200 Enrollment ID: O20121004000289 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
| Entity Name | Mercy Hospital Kingfisher, Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1083048417 PECOS PAC ID: 5395970180 Enrollment ID: O20131104000084 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
| Entity Name | Mercy Hospital Kingfisher, Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1285064618 PECOS PAC ID: 5395970180 Enrollment ID: O20140416000368 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
| Entity Name | Hospitalist Medicine Physicians Of Oklahoma Tcs Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043932486 PECOS PAC ID: 7315315454 Enrollment ID: O20221122001255 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aaron Fry, DO 901 N Porter Ave, Norman, OK 73071-6404 Ph: () - | Aaron Fry, DO 901 N Porter Ave, Norman, OK 73071-6404 Ph: (405) 307-1000 |
News Archive
Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
News outlets report on implementation issues including the declining rate of uninsured people, confusion created by recent administrative changes and a union's assertion that the law will increase inequality.
A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 2 days ago
Jonathan Wright I, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Attention Physician Residency, Norman, OK 73071 Phone: 405-307-5340 | |
Dr. Olivia Danielle Reed, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1000 | |
Dr. Spencer Robert Baird, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 706-296-1258 | |
Dr. Dylan Rommel, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1000 | |
Arthur Maduabia, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-5340 | |
Crystal Helena Goree, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1392 | |
Robert Francisco Sanchez, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1392 |